Insmed To Present at March 2025 Investor Conferences
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its management's upcoming presentations at two major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its management's upcoming presentations at two major investor conferences in March 2025. The company will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, and at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025, at 8:00 a.m. ET.
Both presentations will be available through live webcasts accessible via the investor relations section of Insmed's website at www.insmed.com. The webcasts will remain archived for 30 days after the events conclude.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was +2.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 45th Annual TD Cowen Healthcare Conference in
Boston , on Monday, March 3, 2025, at 9:10 a.m. ET. - Leerink Partners Global Healthcare Conference in
Miami , on Tuesday, March 11, 2025, at 8:00 a.m. ET.
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-march-2025-investor-conferences-302369513.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
